DPT vaccine

DPT is a class of combination vaccines against three infectious diseases in humans: diphtheria, pertussis (whooping cough), and tetanus. The vaccine components include diphtheria and tetanus toxoids and killed whole cells of the bacterium that causes pertussis (wP).

DPT vaccine
DPT/IPV vaccine in Japan
Combination of
Diphtheria vaccineVaccine
Pertussis vaccineVaccine
Tetanus vaccineVaccine
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
ChemSpider
  • none
 NY (what is this?)  (verify)

The usual course of childhood immunization in the United States is five doses between 2 months and 15 years. For adults, Td boosters are recommended every 10 years.

In the late 20th century, vaccinations helped to reduce the incidence of childhood pertussis in the United States. Despite this, reported instances of the disease increased 20-fold in the early 21st century, resulting in numerous fatalities.[1] Over this time, many parents declined to vaccinate their children against pertussis for fear of side effects.[1] In 2009, the journal Pediatrics concluded the largest risk among unvaccinated children was not the contraction of side effects, but rather the disease that the vaccination aims to protect against.[1]

DTP was licensed in 1949.[2]

Combination vaccines with acellular pertussis

DTaP and Tdap are both combined vaccines against diphtheria, tetanus, and pertussis. The difference is in the dosage, with the upper-case letters meaning higher quantity.[3]

DTaP

DTaP (also DTPa and TDaP) is a combined vaccine against diphtheria, tetanus, and pertussis, in which the pertussis component is acellular. This is in contrast to whole-cell, inactivated DTP (DTwP). The acellular vaccine uses selected antigens of the pertussis pathogen to induce immunity. Because it uses fewer antigens than the whole-cell vaccines, it is considered to cause fewer side effects, but it is also more expensive. Recent research suggests that the DTP vaccine is more effective than DTaP in conferring immunity, because DTaP's narrower antigen base is less effective against current pathogen strains.[4]

Tdap

Also, dTpa is a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). It was licensed in the United States for use in adults and adolescents on June 10, 2005.[5] The lower-case "d" and "p" indicated smaller concentrations of diphtheria toxoids and pertussis antigens, and "a" in "ap" indicates that the pertussis toxoids are acellular. Two Tdap vaccines are available in the US. Adacel, manufactured by Sanofi Pasteur, is licensed for use in adults ages 11 to 64. Boostrix, manufactured by GlaxoSmithKline, is licensed for use in adolescents and adults ages 10 to 64. In January 2011, the US's Advisory Committee on Immunization Practices (ACIP) recommended Tdap's use in adults of all ages, including those age 65 and above.[6] In October 2011, in an effort to reduce the burden of pertussis in infants, the ACIP recommended that unvaccinated pregnant women receive a dose of Tdap. On October 24, 2012, the ACIP voted to recommend the use of Tdap during every pregnancy.[7]

The ACIP and Canada's National Advisory Committee on Immunization (NACI) recommended that both adolescents and adults receive Tdap in place of their next Td booster (recommended to be given every 10 years).[8][9][10][11] Tdap and Td can be used as prophylaxis for tetanus in wound management. People who will be in contact with young infants are encouraged to get Tdap even if it has been less than 5 years since Td or TT to reduce the risk of infants being exposed to pertussis. NACI suggests intervals shorter than 5 years can be used for catch-up programs and other instances where programmatic concerns make 5-year intervals difficult.

The World Health Organization recommends a pentavalent vaccine, combining the DTP vaccine with vaccines against Haemophilus influenzae type B and hepatitis B. Evidence on how effective this pentavalent vaccine is compared to the individual vaccines has not yet been determined.[12]

A 2019 study in the American Economic Journal found that state requirements mandating the use of the Tdap vaccine "increased Tdap vaccine take-up and reduced pertussis (whooping cough) incidence by about 32 percent."[13]

In pregnancy

Guidelines on prenatal care in the United States state that if an urgent need for tetanus protection occurs during pregnancy, Td vaccine should be administered.[14] If no urgent need arises and the woman has previously received tetanus vaccine, Td vaccination should be delayed until the postpartum period.[14] All postpartum women who have not received Td or Tdap vaccine in the last two years are recommended to receive Tdap prior to discharge after delivery.[14] Pregnant women who have never received a tetanus vaccine (i.e., have never received DTP, DTaP, or DT as child or Td or TT as an adult) are recommended to receive a series of three Td vaccinations starting during pregnancy to ensure protection against maternal and neonatal tetanus.[14] In such cases, administration of Tdap is recommended after 20 weeks' gestation,[15] and in earlier pregnancy a single dose of Tdap can be substituted for one dose of Td, and then the series completed with Td.[14] The United States' Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) voted to recommend that health-care personnel should administer a dose of Tdap during each pregnancy at 27 through 36 weeks gestation irrespective of the patient's prior history of receiving Tdap.[16]

DTaP and Tdap refer to similar combination vaccines in which the component "P" or "p" with lower case "a" is acellular.

Also available are the DT and Td vaccines, which lack the pertussis component.

In the United Kingdom, the Netherlands, and France, the DTP vaccine is combination vaccine against diphtheria, tetanus, and poliomyelitis. In the Netherlands, pertussis is known as kinkhoest and DKTP refers to a combination vaccine against diphtheria, kinkhoest, tetanus, and polio.

References

  1. "Is Vaccine Refusal Worth The Risk?". NPR. National Public Radio. 2009-05-26. Retrieved 2009-06-19.
  2. "Vaccine Timeline: Historic Dates and Events Related to Vaccines and Immunization". Immunization Action Coalition. 2013-05-17. Retrieved 2014-06-25.
  3. "The difference between Tdap and DTaP; dabigatran versus warfarin". JAAPA. Retrieved 2014-06-25.
  4. Higgs, Higgins, Ross and Mills 2012 'Immunity to the respiratory pathogen Bordetella pertussis' Mucosal Immunol 5(5):485-500
  5. "Preventing Tetanus, Diphtheria, and Pertussis Among Adults: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and Recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for Use of Tdap Among Health-Care Personnel". MMWR Morb. Mortal. Wkly. Rep. 55: 1–33. December 15, 2016.
  6. Centers for Disease Control Prevention (CDC) (January 2011). "Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010". MMWR Morb. Mortal. Wkly. Rep. 60 (1): 13–5. PMID 21228763.
  7. "Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women — Advisory Committee on Immunization Practices (ACIP), 2012". MMWR Morb. Mortal. Wkly. Rep. 62 (7): 131–135. February 22, 2013.
  8. Broder KR, Cortese MM, Iskander JK, et al. (Mar 2006). "Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR Recomm Rep. 55 (RR–3): 1–34. PMID 16557217., page 18.
  9. "ACIP Votes to Recommend Use of Combined Tetanus, Diphtheria and Pertussis (Tdap) Vaccine for Adults" (PDF). CDC.gov. Centers for Disease Control and Prevention. Archived from the original (PDF) on 2006-10-19.
  10. "Interval Between Administration of Vaccines Against Diphtheria, Tetanus, and Pertussis". PHAC-ASPC.GC.ca.
  11. Kretsinger K, Broder KR, Cortese MM, et al. (December 2006). "Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel". MMWR Recomm Rep. 55 (RR–17): 1–37. PMID 17167397.
  12. Bar-On ES, Goldberg E, Hellmann S, Leibovici L (2012). "Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB)". Cochrane Database Syst Rev. 4 (4): CD005530. doi:10.1002/14651858.CD005530.pub3. PMID 22513932.
  13. Lawler, Emily C.; Carpenter, Christopher S. (2019). "Direct and Spillover Effects of Middle School Vaccination Requirements". American Economic Journal: Economic Policy. 11 (1): 95–125. doi:10.1257/pol.20170067. ISSN 1945-7731.
  14. Health Care Guideline: Routine Prenatal Care. Fourteenth Edition. Archived June 24, 2012, at the Wayback Machine By the Institute for Clinical Systems Improvement. July 2010.
  15. Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) in Pregnant Women and Persons Who Have or Anticipate Having Close Contact with an Infant Aged <12 Months, 2011 - section "Safety of Tdap in Pregnant Women". By the Advisory Committee on Immunization Practices), at Centers for Disease Control and Prevention.
  16. "ACIP provisional updated recommendations on use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) for pregnant women" (PDF). Archived from the original (PDF) on January 23, 2013. Retrieved September 9, 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.